Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18023427 | 1.00 | HCRTR1 (0.40) | HCRTR1HCRTR2KDM4EHPGDHSP90AA1 | |
| SCHEMBL19447291 | 1.00 | HCRTR1 (0.40) | HCRTR1HCRTR2KDM4EHPGDHSP90AA1 | |
| SCHEMBL19447543 | 1.00 | HCRTR1 (0.40) | HCRTR1HCRTR2KDM4EHPGDHSP90AA1 | |
| SCHEMBL15073051 | 0.94 | HCRTR1 (0.40) | HCRTR1HCRTR2HSP90AA1HSP90AB1 | |
| SCHEMBL19447616 | 0.94 | HCRTR1 (0.40) | HCRTR1HCRTR2HSP90AA1HSP90AB1 | |
| SCHEMBL2737696 | 0.93 | HSP90AA1 (0.38) | HCRTR1HCRTR2HSP90AA1HSP90AB1 | |
| SCHEMBL2738268 | 0.93 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL15077257 | 0.92 | HCRTR1 (0.40) | HCRTR1HCRTR2KDM4EHPGDHSP90AA1 | |
| SCHEMBL18022007 | 0.92 | HCRTR1 (0.40) | HCRTR1HCRTR2KDM4EHPGDHSP90AA1 | |
| SCHEMBL15073067 | 0.92 | HCRTR1 (0.37) | HCRTR1HCRTR2HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794611-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2013096681-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | HCRTR1 4565/4885HCRTR2 4849/4885KDM4E 2068/4885 |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | HCRTR1 4161/4885HCRTR2 4221/4885KDM4E 4080/4885 |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | HCRTR1 4565/4885HCRTR2 4849/4885KDM4E 2068/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | HCRTR1 4565/4885HCRTR2 4849/4885KDM4E 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.